Immunomonitoring of Mold Invasive Infections (NCT06285188) | Clinical Trial Compass
RecruitingNot Applicable
Immunomonitoring of Mold Invasive Infections
France20 participantsStarted 2025-07-28
Plain-language summary
Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* Mold invasive fungal infection: Aspergillus, Mucorales, Fusarium, Scedosporium
* Proven or probable according to 2019 EORTC/MGS criteria modified by the adjunction of diabetes mellitus in the host criteria and Mucorales PCR in the microbiological criteria
* Within 14 days of IFD diagnosis or
* a refractory state defined by the 2009 MGS/EORT failure criteria (clinical, radiological, or microbiological failure) of a first-line antifungal treatment leading to a change of therapy by the attending physician of the patient
* Patients with aspergillosis or mucormycosis for whom ELISPOTs are developed: Total lymphocyte count \> 700/mm3 on the last sample taken
* No opposition to participate to the research
* Affiliated or beneficiary of social security system
Exclusion Criteria:
* Bacterial co-infection in the last 14 days
* Previous treatment with anti-PD1 antibodies